Генетический полиморфизм тиопуринметилтрансферазы (ТПМТ) у детей с острыми лейкозами, жителей Российской Федерации
Диссертация
Показатель долгосрочной выживаемости детей с острым лимфобластным лейкозом (OJIJI) в настоящее время достиг 80%, что свидетельствует об эффективности риск-адаптированной терапии, применяемой в современных протоколах лечения как в западных клиниках (Pui СН et al., 2004), так и в нашей стране (А.И. Карачунский, 1999). Основной причиной неудач в терапии OJIJI по-прежнему остается рецидив заболевания… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. ГЕНЕТИЧЕСКИЙ ПОЛИМОРФИЗМ ТИОПУРИН МЕТИЛТРАНСФЕРАЗЫ И
- ЕГО КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ. (ОБЗОР ЛИТЕРАТУРЫ)
- Открытие фермента тиопурин-Б-метилтрансферазы
- Роль ТПМТ в метаболизме тиопуриновых препаратов
- Индивидуальные различия в метаболизме меркаптопурина и риск рецидива у детей с
- Активность ТПМТ и тиопуриновая токсичность
- Генетический полиморфизм и аллели ТПМТ
- Молекулярная диагностика недостаточности ТПМТ
- Влияние генотипа ТПМТ на толерантность тиопуринов
- Прогностическое значение дозирования 6-МП у детей с ОЛЛ
- Генетический полиморфизм ТПМТ и вторичные опухоли у детей с ОЛЛ
- Популяционные исследования
- Фармакогенетика и индивидуализация терапии
- ГЛАВА 2. ПАЦИЕНТЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- Характеристика пациентов
- Определение мутаций в гене ТПМТ методом мультиплексной ПЦР и гибридизации с микрочипом
- Определение событий для пациентов с ОЛЛ
- Включение пациентов с ОЛЛ в анализ токсичности 6-меркаптопурина
- Классификация рецидивов ОЛЛ и определение событий
- Анализ результатов генотипирования пациентов с гемобластозами
- Анализ токсичности 6-МП у пациентов с ОЛЛ
- Анализ эффективности лечения 6-МП у пациентов с ОЛЛ
- ГЛАВА 3. РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ
- Результаты генотипирования пациентов
- Идентификация аллелей гена ТПМТ
- Результаты распределения пациентов по этническим группам
- Пациенты с острым лимфобластным лейкозом
- Сравнительный анализ токсичности 6-МП в группах гетерозиготных пациентов и пациентов «дикого типа» на консолидирующей терапии
- Сравнительный айализ эффективности терапии 6-МП в группах гетерозиготных пациентов и пациентов «дикого типа»
- Пациенты с рецидивом острого лимфобластного лейкоза
- Пациенты с неходжкинскими лимфомами
- Пациенты с острым миелоидным лейкозом
- КЛИНИЧЕСКИЕ ПРИМЕРЫ
- ГЛАВА 4. ОБСУЖДЕНИЕ РЕЗУЛЬТАТОВ
- ВЫВОДЫ
Список литературы
- Карачунский А.И., 1999. Стратегия терапии острого лимфобластного лейкоза у детей. М.: Автореферат докт. мед. наук.
- Крынецкая Н.Ф., Крынецкий Е. Ю. Мишени антилейкозных агентов: молекулярные механизмы действия меркаптопурина. Молекулярная биология 2000, т. 34, № 6, с. 1046−1053.
- Самочатова Е.В., Карачунский А. И., Мякова Н. В., Руднева А. Е., Трубина Н. М., Чупова Н. В., Румянцев А. Г. Активность тиопуринметилтрансферазы у детей с острым лимфобластным лейкозом. Гематология и трансфузиология 2002, т.47, № 6, с. 17−20.
- Тишков В.А. (гл.ред.). Большая Российская Энциклопедия «Народы и религии мира», М: 1998.
- Albertini RJ, O’Neil JP, Nickals JA, Heintz NH, Kelleher PC. Alterations of the hprt gene in human in vivo-derived 6-thioguanine-resistant T lymphocytes. Nature 1985- 316: 369−371.
- Ameyaw MM, Collie-Duguid ESR, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genetics 1999, Vol 8, N0 2, 367−370.
- Black AJ, Mc Leod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ESR, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Inter Med 1998−129:716−718.
- Boddy A, Idle J. The role of pharmacogenetics in chemotherapy: modulation of tumor response and host toxicity. Cancer Sur 1993- 17: 79 104.
- Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosphamide activation. Pharmacogenetics 1997- 7: 211−221.
- Colli~Duguid ESR, Prichard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999- 9: 3742.
- Coulthard SA, Howell C, Robson J, Hall AG. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998, 92, 8, 2856−2862.
- Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutation S-transferasea alpha, muandpi. Drug Metab Dispos 1996- 24: 1015−1019.
- Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihidropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fliiorouracil-induced toxicity. J Clin Invest 1988−81:47−51.
- Elion GB. The purine path to chemotherapy. Science 1989- 24: 441−447.
- Evans WE, Horner M, Chu YQ, Kalwinsky DK, Roberts M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methy? transferas e-deficient child with acute lymphocytic leukemia. J Pediatr 1991- 119:985−9.
- Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987- 56: 339−47.
- Hewlett JS, Bodey GP, Wilson HE, Stuckey WS. Combination 6-mercaptopurine and 6-methylmercaptopurine riboside in the treatment of adult acute leukemias: a Southwest Oncology Group Study. Cancer Treat Rep 1979- 63: 156−8.
- Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-American. Hum Mol Genetics 1999, Vol 8, No 2, 371−376.
- Iyer L, Ratain MJ. Pharmacogenetics and Cancer Chemotherapy. Eur J Cancer 1998, Vol 34, No 10, 1493−1499.
- Jacqz-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E. Thiopurine methyl transferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994- 38: 1−18.
- Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyl transferase activity. Scand J Clin Lab Invest 1993- 53: 747−9.
- Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 2000- 14: 2339−2344.
- Krynetski EY, Evans EE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S~methyltransferase paradigm. PharmRes 1999, 16(3): 342−9.
- Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000 Sep- 61(3): 136−46. Review.
- Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Him Genet 1998, 63: 11−16.
- Krynetski EY, Evans WE. Drug methylation in cancer therapy: lessons from the TPMTpolymorphism. Oncogene 2003, 22: 7403−7413.
- Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans E. Methylation of mercaptopurine, thioguanine and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol 1995a- 47: 1141−1147.
- Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc.Natl.Acad.Sci.USA 1995b- 92 Feb: 949−953.
- Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996- 6: 279−290.
- Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, Konishi F, Maeda H, Yamakido M. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics.2001 Apr-275−8.
- Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity duringtreatment for acute lymphoblastic leukaemia. Arch Dis Child 1993- 69: 577 579.
- Lennard L, Jon A. Van Loon, Weinshiboum RM. Pharmogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46:149−54.
- Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukaemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pfarmacol Ther 1986- 40: 287−292.
- Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS. Thiopurine methyltransferase deficiency in childhood lymphoblastic leulaemia: 6-mercaptopurine dosage strategies. Medical and Pediatric Oncology 1997- 29: 252−255
- Lennard L, Lilleyman JS, Loon JV, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990−336: 225−29.
- Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989, Vol 7, No 12:1816−1823.
- Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatog 1987- 423: 169−78.
- Lennard L. The clinical pharmacology of 6-mercaptopurine. Evr J Clin Pharmacol 1992- 43: 329−339.
- Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol 2001−52 Suppl 1:75S-87S. Review.
- Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddockos JL. Childhood lymphoblastic leukemia: sex difference in 6-mercaptopurine utilization. Br J Cancer 1984−49:703−7.
- Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994−343−5(14): 1188−90.
- Lipp HP et al. (book). Anticancer drug toxicity. Prevention, management and clinical pharmacokinetics. 1999 Chapter 8.3 p 392−421. Lipp HP, Boos S, Verspohl EJ, Krynetski EY, Evans WE. Hepatotoxicity induced by cytostatic drugs.
- Luce JK, Frenkel EP, Vietti TJ, Isassi AA. Clinical studies of 6-methylmercaptopurine riboside (NSC-40 774) in acute leukemia. Cancer Chemother Rep 1967- 51: 535−46.
- McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson ES. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol. 1999, 105:696−700.
- McLeod HL, Krynetski E. Y, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000 Apr- 14(4): 56 772. Review.
- McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995- 5: 281−286.
- McLeod HL, Lin JS, Scott MC, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994- 55: 15−20.
- McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995, 85, 7, 1897−1902.
- McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus -implications for clinical pharmacogenomics. Pharmacogenomics 2002, Jan-3(l):89−98.
- Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996- 15: 273−280.
- Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997- 60: 265 271.
- Neglia JP, Meadows AT, Robinson LL, et al. Second neoplasma after acute lymphoblastic leukemia in childhood. N Engl J Med 1991- 325: 1330−36.
- Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998- 101: 1036−1044.
- Pacifici GM, Romiti P, Santerini S, Giuliani L. S-methyltransferases in human intestine: differential distribution of the microsomal thiol methyltransferase and cytosolic thiopurine methyltransferase along the human bowel. Xenobiotica 1993- 3: 671−679.
- Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand 1986- 548: 89−99.
- Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-relatedmyelodysplasia and acute nonlymphocytic leukemia. Blood 1990- 76:108 391.
- Pinkel D. Intravenous mercaptopurine: life begins at 40. J Clin Oncol 1993- 11: 1826−31.
- Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia — current status and future perspectives. Lancet Oncol 2001- 2: 597−607.
- Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophylotoxins. Leukemia 1995- 9: 1680−4.
- Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Annals of Hematology 2004- Suppl 1 to Vol 83: 124−6.
- Ratain MJ, Mick R, Berezin F, Janish L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991- 50: 573−579.
- Relling MV, Davies S. Pharmacogenetics of acute lymphoblastic leukemia. American Society of Hematology 2003: 108−112.
- Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Kiynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S^methyhransferase gene locus. J Natl Cancer Inst. 1999a Dec 1- 91(23):2001-&
- Relling MV, Michael L. Hancock, James M. Boyett, Ching-Hon Pui, and William E. Evans Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia Blood 1999c- 93: 2817−2823.
- Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998 Mar- 12(3): 346−52.
- Remy CW. Metabolism of thiopyrimidines and thiopurines. J Biol Chem 1963- 238: 1078−1084.
- Rosso P, Terracini B, Fears TR, et al. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Int J Cancer 1994- 59: 451−56.
- Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosupression in thiopurine methy? transferase deficient heart transplant recipient letter. Lancet 1993- 341: 436.
- Shrappe M. Evolution of BFM trials for childhood ALL. Annals of Hematology 2004- Suppl 1 to Vol 83: 121−3.
- Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, Evans WE, Kriwacki RW. Structure and dynamics of thioguanine-modified duplex DNAJ Biol Chem 2003- 278: 1005−1011.
- Stanulla M, Loening L, Welte K, Schrappe M. Secondary brain tumours in children with ALL letter. Lancet 1999- 354: 1126−1127.
- Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methy? transferase pharmacogenetics: biochemical properties, liver — erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992−2:148−59.
- Thomsen JB, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Wenshilboum R, Andersen JB, Schmiegelow K. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Canser. 1999 Sep 15- 86(6): 1080−6.
- Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974- 34: 738 —746.
- Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 1982- 20: 637−58.
- Van OS EC, Zins BJ, Sandbom WJ, Mays DC, Tremaine WJ, Mahoney DW, Zinmeister AR, Lipsky JJ. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996- 39: 63−68.
- Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihidropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996- 98: 610−615.
- Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase- radiochemical microarray and biochemical properties. Clin Chem Acta 1978- 85: 323−33.
- Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980- 32: 651−662.
- Woodson LC, Dunnette JH, Wenshilboum RM. Pharmacogenetics of human thiopurine—methyltransferasei? kidney-erythrocyte correlation and immunotitration studies. J Pharmacol 1983- 32: 819−8267
- Woodson LC, Weinshilboum RM. Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol 1983- 32: 819−826.
- Working Party on leukaemia in childhood. Improvement in treatment for children with acute lymphoblastic leukaemia: the Medical Research Council UKALL Trials, 1972−84. Lancet 1986- 1: 408−11.
- Zimm S, Collins JM, O’Neil D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy. Interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983−34: 810−817.
- Zimm S, Collins JM, Riccardi R, O’Neill D, Narang PK, Chabner B, Poplack DG. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983- 308: 1005−1009.